TCM
ECYT

Teza Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Teza Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,542
Closed -$37K – 631
2016
Q4 		$37K Buy
+14,542
New +$41.8K 0.05% 229

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Teza Capital Management's ECYT Position: Q1 2017 in Review

Teza Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2017, closing a stake of 14,542 shares — an estimated $37K sold.

Teza Capital Management first reported a position in ECYT in Q4 2016 and held it in 1 quarter. The position peaked at $37K in Q4 2016. 82 funds tracked by Wall St. Rank hold ECYT as of Q1 2017.

  • Teza Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Teza Capital Management sold 14,542 Endocyte, Inc. Common Stock shares in Q1 2017, an estimated $37K.
  • Teza Capital Management first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 1 quarter.
  • Teza Capital Management's Endocyte, Inc. Common Stock position peaked at $37K in Q4 2016.
  • 82 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2017.

Based on Teza Capital Management's 13F filing for Q1 2017, filed 4 May 2017.